natgillin/translations-raw huggingface dataset:
No. 5,240,711 to Hille, et. al.; (assigned to LTS Lohmann Therapie-Systeme GmbH & Co.), hereby incorporated by reference. 
Pat. No. 5,240,711 (dodijeljen LTS Lohmann Terapie-Systeme GmbH & Co.).
is CR10 (wherein R10 is a hydrogen atom, an optionally protected carboxyl group, an optionally substituted carbamoyl group, an optionally substituted C1-6 alkyl group or an optionally substituted aryl group) or a nitrogen atom; 
je CR10 (pri čemu je R10 atom vodika, po izboru zaštićena karboksilna skupina, po izboru supstituirana karbamoilna skupina, po izboru supstituirana C1-6 alkilna skupina ili po izboru supstituirana arilna skupina) ili atom dušika;
A method for coagulation of suspended particles of oil, oil products, or metal ions by introducing a coagulation agent based on an organic polymer to water contaminated with the oil, oil products, or metal ions, wherein the coagulation agent includes an aqueous solution of polysaccharide microgels with a molecular mass of 20,000-200,000 Da and a particle size of 50-600 nm, wherein a concentration of the polysaccharide microgels is 0.1-20 g/l. 
- = uvođenje u spomenutu vodu agensa koagulacije sastojeći se od vodene otopine polisaharidnih mikrogelova s molekularnom masom od 20.000 do 200.000 Da i veličinom čestice od 50 do 600 nm, spomenuta otopina imajući koncentraciju mikrogelova koja nije manja od 0.1g/l, tako da nakon tretmana spomenute lebdeće čestice nafte ili naftnih proizvoda bivaju premazane tankom polisaharidnom opnom;
The granulate may then be tableted, or other excipients may be added prior to tableting, such as a glidant and/or a lubricant. 
Granulat se može tabletirat, ili se prije tabletiranja mogu dodati druge pomoćne tvari kao npr. sredstva za klizanje i/ili lubrikanti.
Method according to claim 1, characterized in that plywood, fibreboard or chipboard are used as a substrate. 
Postupak prema zahtjevu 1, naznačen time, da se kao podloga koristi šperploča, vlaknasta ploča 1li iverica.
The method as defined in claim 8, wherein when the magnitude relationship as a result of the comparison in the comparator exceeds the predetermined value and the value exceeding the predetermined value continues a predetermined number of times within a predetermined time period, a value as a time constant is controllably changed. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što dodatno uključuje korak upravljivog mijenjanja vrijednosti u obliku vremenske konstante, kada odnos veličina kao rezultat usporedbe u komparatoru premašuje zadanu vrijednost, a vrijednost koja premašuje zadanu vrijednost se nastavlja zadani broj puta u zadanom vremenskom periodu.
Since the operational time of an oil rig is typically costed in tens of thousands of dollars per day it is essential that rig operators recover stuck tooling as quickly as possible. 
Budući da se vrijeme rada jedne garniture za bušenje procjenjuje na desetak tisuća dolara na dan, izuzetno je važno da operator izvuče dio zaostalog alata što je moguće prije.
Alternatively the amide of formula (1) may be prepared by reacting a mixed anhydride derived from the carboxylic acid (11) with the amine NHR4R5 in an aprotic solvent such as tetrahydrofuran. 
Alternativno se amid formule (1) može dobiti reakcijom miješanog anhidrida, dobivenog iz karboksilne kiseline (11) s aminom NHR4Rs, u neprotonskom otapalu, poput tetrahidrofurana.
A bispecific molecule comprising the antibody or antigen-binding portion of any one of claims 1 to 6, linked to a second functional moiety having a different binding specificity than said antibody or antigen-binding portion. 
Bispecifična molekula koja sadrži protutijelo ili dio koji veže antigen prema bilo kojem od zahtjeva 1 do 4, koja je povezana s drugim funkcionalnim dijelom koji ima drugačiju specifičnost vezanja od tog protutijela ili dijela koji veže antigen.
The assay results indicated that at least 99.5% of ET-743 remained after 9 months of storage at −20° C., at least 99% of ET-743 remained after 9 months of storage at 4° C., and at least 97% of ET-743 remained after 9 months of storage at 25° C./60% RH. 
Rezultati testa pokazali su da je najmanje 99.5% ET-743 preostalo poslije 9 mjeseci čuvanja na -20%C, najmanje 99% ET-743 je preostalo poslije 9 mjeseci čuvanja na 4*C i najmanje 97% ET-743 je preostalo poslije 9 mjeseci čuvanja na 25%C/60% relativne vlažnosti.
If fusible fibres are present, the heating can take place as thermal after-treatment of the elastic, conductive hybrid yarn, which can, for example, be combined with a rewinding process, or even during the subsequent textile finishing of the finished fabric. 
Ako su prisutna topljiva vlakna, zagrijavanje se može provesti kao naknadna toplinska obrada elastično vodljive hibridne pređe, koja može, na primjer, biti kombinirana s postupkom ponovnog omatanja, ili čak za vrijeme sljedeće dorade tekstila gotovog plošnog tekstilnog proizvoda.
The method according to Claim 4 wherein the polyester is polyethylene terephthalate, polybutylene terephthalate, polytrimethylene terephthalate, or polyethylene naphthalate. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time, da je poliester polietilen tereftalat, polibutilen tereftalat, politrimetilen tereftalat ili polietilen naftalat.
According to one embodiment of the present invention, the inkjet-printed substrate is used in packaging applications, in decorative applications, in artistic applications, or in visual applications. According to one embodiment, the inkjet-printed substrate is used as wall paper, packaging, gift wrap paper, advertisement paper or poster, business card, manual, warranty sheet or card. 
Uporaba tintom otisnute podloge prema zahtjevu 10 naznačena time da je za primjenu za ambalažu, za dekorativne primjene, umjetničke primjene, vizualne primjene, poželjno kao tapete, ambalaža, papir za omatanje poklona, papir za oglašavanje ili za postere, za posjetnice, priručnike, jamstvene listove ili kartice.
Another aspect of the invention is a method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound or the pharmaceutical composition as described herein. 
Spoj prema zahtjevu 1, ili farmaceutski sastav prema zahtjevu 2, naznačen time, da se upotrebljava u liječenju bolesti ili poremećaja povezanih sa nekontroliranim, nenormalnim i/ili neželjenim staničnim djelovanjima. Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak želudca.
A compound according to claim 1, wherein R2 is independently selected from F, Cl, CF3, and CHF2. 
Spoj u skladu sa patentnim zahtjevom 1, gdje R* je nezavisno odabran od F, CI, CF, i CHF,.
The term “salts” herein refers to both salts of carboxyl groups and to acid addition salts of amino groups of IL-18 inhibitor molecule, or analogs thereof. 
Pojam «soli» ovdje se odnosi na soli i na karboksilne skupine te na kisele adicijske soli amino skupina iz inhibitorne moleklule za IL-18BP ili njihovi analozi.
The composition of claim 1, the compound represented by a structure of Formula 9 or stereoisomer thereof or pharmaceutically acceptable salt thereof: 
Sastav iz patentnog zahtjeva 1, tvar sadrži strukturu Formule 9 ili njen stereoizomer ili njenu farmaceutski prihvatljivu sol.
decoding the PLP from the parsed signal frame. 
pa. organiziranje sloj-2 informacije u pilot okvira signala
The hybrid electric drive unit according to claim 1, characterized in that the drive disc of the first clutch is directly connected to a rotor support of the second motor. 
Hibridna električna pogonska jedinica prema bilo kojem od zahtjeva 1 do 8, naznačena time, da je pogonski disk prve spojke (6) izravno spojen na nosač rotora (16) drugog motora (3).
Such an arrangement does not provide stiffness and mechanical resistance to the radial stress exerted by a rolled film on the core. 
Takva izvedba ne pruža čvrstoću i mehaničku otpornost protiv radijalne sile koju vrši folija namotana na jezgru.
A pharmaceutical composition comprising a compound of the formula: or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle. 
[image] ili njegova farmaceutski prihvatljiva sol i farmaceutski prihvatljiv nosač, katalizator ili prenositelj.
A pharmaceutical formulation for use in the treatment of cell differentiation and proliferation-related diseases, which is characterized in that the pharmaceutical formulation comprises the chidamide crystal form A according to claim 1 and pharmaceutically acceptable excipients. 
Farmaceutski pripravak za korištenje u liječenju bolesti vezanih uz staničnu diferencijaciju 1 proliferaciju, koji je naznačen time što farmaceutski pripravak sadrži kristal kidamida oblika A u skladu sa zahtjevom 1 i farmaceutski prihvatljive pomoćne tvari.
admixing methyl 4-(3-amino-2-fluorobenzyl)piperazine-1-caboxylate and phenyl (6-methylpyridin-3-yl)carbamate in the presence of a trialkylamine base to form omecamtiv mecarbil as a free base; and crystallizing the omecamtiv mecarbil free base in the presence of aqueous hydrochloric acid and an alcohol solvent to form omecamtiv mecarbil dihydrochloride hydrate salt. 
(b) miješanje metil 4-(3-amino-2-fluorobenzil)piperazin-1-karboksilata i fenil (6-metilpiridin-3-il)karbamata u prisutnosti trialkilamin baze kako bi nastao omekamtiv mekarbil kao slobodna baza; i (c) kristaliziranje slobodne baze omekamtiv mekarbila u prisutnosti vodene klorovodične kiseline i alkoholnog otapala kako bi nastala dihidroklorid hidratna sol omekamtiv mekarbila.
printing said marking thereon using an ink of the conventional type; applying a thermochromic ink, which is coloured below the temperature of about 38° C., but becomes colourless when said temperature is reached, so that said marking is substantially invisible below said temperature, but becomes visible when said temperature is reached or exceeded. 
(c) navedeni prvi odsječak (2', 12') 1 drugi odsječak (2", 12") su raspoređeni tako, da je navedeni prvi odsječak (2', 12') nevidljiv ispod temperature od oko 38C, ali postaje vidljiv kada se dosegne navedena temperatura ili kada se ona prijeđe; i
A method of increasing production of saleable maize seed from a hybrid seed production field, comprising treating said field with a defoliation means. 
PATENTNI ZAHTJEVI wanman ao Način za povećanje proizvodnje utrživog sjemena kukuruza iz polja za proizvodnju hibridnog sjemena, koji se sastoji od:
obtaining a solution of the gadobenate dimeglumine in a solvent A selected from the group consisting of water, aqueous solvents, organic solvents having a log P value no greater than −0.5, and mixtures thereof, wherein the amount by weight of the water optionally present in the solution is no more than the amount by weight of the gadobenate dimeglumine in the solution; 
dobivanje otopine gadobenat dimeglumina u otapalu A odabranom od vode, vodenih otapala, organskih otapala koja imaju vrijednost log P jednaku ili manju od -0.5 i njihovih smjesa, pri čemu masena količina vode koja je proizvoljno prisutna u otopini iznosi najviše jednako ili manje od masene količine gadobenat dimeglumina sadržanog u otopini;
The application of the combinations according to the invention can be for instance once a day, or depending on the duration of action of the anticholinergic agent twice a day, or once every 2 or 3 days, or even on an "as needed" basis (three or more times a day on occasional days). 
Kombinacije sukladno predmetnom izumu mogu se davati jedanput na dan ili, ovisno o trajanju djelovanja antikolinergijskog sredstva, dvaput na dan ili jedanput svaka 2 ili 3 dana. HR P20090106 T3
The method of claim 7, wherein said treating comprises treating alcoholic steato-hepatitis. The pharmaceutical composition of claim 6, which is formulated for oral, parenteral, subcutaneous, intravenous, intramuscular, nasal, topical or rectal administration. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 6 do 9, naznačen time što je formuliran za oralnu, parenteralnu, supkutanu, intravensku, intramuskularnu, nazalnu, topikalnu ili rektalnu primjenu, i/ili što sadrži jednu ili više farmaceutski prihvatljivih pomoćnih tvari.
HyQual™ 5712 magnesium stearate in an amount of about 0.5% by weight of the total composition; and 
HyQual"M 5712 magnezijev stearat u količini od oko 0.5 masenih % cjelokupnog pripravka; i i.
The compound of paragraph 17 having a structure selected from the group consisting of: and 
Spoj prema zahtjevu 1, naznačen time da ima strukturu odabranu iz skupine koja sadrži:
The method of claim 1, wherein the decolorization is achieved by using activated charcoal at an amount ranging from 0.05-0.3% by weight of the injection. 
Postupak prema patentnom zahtjevu 8, gdje se dekolorizacija postiže upotrebom aktiviranog ugljena u količini od 0.05-0.3 wt% injekcije.
and R5, taken together with the intervening oxygen and boron atoms, form an optionally substituted chiral cyclic boronic ester; said process comprising: 
R' i R', uzeti zajedno sa atomima kisika i bora koji se nalaze između, formiraju izborno supstituirani hiralni ciklični ester organoborne kiseline; pri čemu navedeni postupak sadrži:
All fatty acid alkyl esters contain a reactive group i.e. 
Svi alkil esteri masnih kiselina sadrže reaktivnu skupinu, tj.
an upwardly angled channel comprising a sliding surface; a plurality of water spray sources positioned to spray water over the sliding surface; an amusement ride vehicle comprising: a body comprising water impact surfaces spaced along opposite sides of the vehicle body, the water impact surfaces being adapted to affect upward motion of the vehicle when the water impact surfaces are impacted by a flow of water from the plurality of water spray sources; 
Postupak za potiskivanje vozila da klizi prema gore na donjoj površini vozila duž klizne površine kanala vodenog tobogana naznačen time što obuhvaća udaranje vode u udarne površine za vodu koje su razmaknute uzduž suprotnih strana tijela vozila s mnoštvom izvora za raspršivanje vode smještenim da osiguravaju strujanje vode preko klizne površine 1 prilagođenim da utječu na klizno kretanje vozila.
Subsequently, the pre-treating step may according to another aspect of the invention comprise a step of size reducing of the material such as a cutting, grinding, milling, or sieving step or a combination thereof. 
Metoda u skladu s patentnim zahtjevom 2, pri čemu korak predtretiranja obuhvaća korak smanjenja veličine materijala kao što je rezanje, glodanje, mljevenje, ili korak prosijavanja ili njihova kombinacija.
wherein R1, R2, R3, m, n and q are as defined above with a compound represented by the formula (V): A-NH2, wherein A is as defined above. 
(e), pri čemu R', R', R*, m, ni q su kako je gore definirano, sa spojem predstavljenog formulom (V): A-NH>, pri čemu je A gore definirano.
introducing a capsule (1, 1') according to any of claims 1 to 10 in an extraction (10) chamber, 
- < umetanje kapsule (1, 1') u skladu s bilo kojim od patentnih zahtjeva 1 do 10 u ekstrakcijsku (10) komoru,
The holding device (110) according to claim 1, characterized in that the connecting element (119) is guided in the foot section (116) in such a way that the holding device (110) is self-locking. 
Naprava za držanje (110) prema jednom od prethodnih patentnih zahtjeva, naznačena time što se spojni element (119) vodi u dijelu stopala (116) na takav način da je naprava za držanje (110) samodostatna.
where not more than one (1) or two moieties selected from D1, D2, D3, D4 and D5 are a heteroatom; ◯ is an aromatic system; and 
Dsje C-R'"ili N; gdje ne više od jedne (1) ili dvije skupine koje su odabrane od D,, D>, D:, Du 1 Ds su heteroatom; je aromatski sustav; i
wherein said surfactant is about 0.004% w/v polysorbate-20; and lyophilizing said therapeutic peptibody; 
navedeni stabilizator je 2 % w/v saharoza; i navedena površinski aktivna materija je 0.004% w/v polisorbat-20; ili
7B . In a similar embodiment, shown in FIGS. 8A and 8B, the walls of the constraint portion 18 at the pocket 24 comprise through holes 25 so aligned as to allow inserting a securing pin (not shown) before or after locking by compression as described above. 
Karabiner (1) u skladu s patentnim zahtjevom 9, naznačen time što stijenke dijela za zadržavanje (18) kod džepa (24) ima provrte (25) koji su tako orijentirani da omoguće umetanje osigurača prije ili nakon zabravljivanja pritiskom.
To the filtrate plus a 1 mL DCM wash of the solids 100mg of IRC-50 ion-exchange resin was added. 
Filtratu plus 1 mL DCM tekućine od ispiranja krutina je bilo dodano 100 mg IRC-50 10n-izmjenjivačke smole.
wherein the last significant coefficient location of the current transformation block is reconstructed by combining the inverse-binarized prefix and the inverse-binarized suffix, and wherein the reconstructed last significant coefficient location indicates one of information about a x coordinate of the last significant coefficient location in a direction of widths of the current transformation block and information about a y coordinate of the last significant coefficient location in a direction of heights of the current transformation block, wherein the predetermined value is classification point between the prefix bitstring and the suffix bitstring, wherein the inverse-binarized suffix is a remaining value of a symbol indicating the last significant coefficient location of the transformation block after the inverse-binarized prefix is excluded from the symbol. 
aritmetički dekoder koji je konfiguriran za provođenje kontekstnog aritmetičkog dekodiranja na prefiksu niza bitova mjesta zadnjeg značajnog koeficijenta između informacija o mjestu zadnjeg značajnog koeficijenta, i, kada je prefiks niza bitova veći od prethodno određene vrijednosti, provođenje zaobilaznog načina aritmetičkog dekodiranja na sufiksu niza bitova mjesta zadnjeg značajnog koeficijenta između informacija o mjestu zadnjeg značajnog koeficijenta;
The considerable thickness of the sampling tube which is to be introduced compared to the prior art (from approximately 1 cm and preferably approximately 2 cm) makes it easier to feel for the user. 
Znatna debljina cijevi naprave za uzimanje uzorka, koja cijev se treba uvesti (promjera približno od 1 cm, a poželjno 2 cm), u usporedbi sa stanjem tehnike olakšava da korisnica osjeća cijev.
Typically the delivery system of this particular invention further comprises a polymeric moiety selected from polyethylene glycol (PEG), polyvinylpyrrolidone (PVP) and polyoxypropylene/polyoxyethylene block copolymers (poloxamers). 
Smjesa prema zahtjevu 2, gdje se polimerni dio izabire iz skupine koja obuhvaća polietilen glikol (PEG), polivinil pirolidon (PVP) 1 polioksipropilen/polioksietilen blok kopolimere (poloksameri).
is a C5-10 aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, C1-7 alkoxy, C5-20 aryloxy, C3-20 hetercyclyloxy, C1-7 alkyl, C3-7 heterocyclyl and bis-oxy-C1-3 alkylene, wherein the C1-7 alkoxy group may be substituted by an amino group, and if the C3-7 heterocyclyl group is a C6 nitrogen containing heterocyclyl group, it may be substituted by a C1-4 alkyl group; 
R'je Cs.o aril-skupina, opcijski supstituirana s jednim ili više supstituenata odabranih iz skupine koju čine: halo, nitro, cijano, Ci; alkoksi, Cs.29 ariloksi, C2.)9 hetercikliloksi, Ci.7 alkil, C3.; heterociklil 1 bis-oksi-C,.3 alkilen, pri čemu C1; alkoksi-skupina može biti supstituirana s amino-skupinom, i ako je C3.; heterociklil-skupina takva da je to heterociklil-skupina koja sadrži Cg nitrogen, tada može biti supstituirana s C,_., alkil-skupinom;
L is a linker selected from the group consisting of -NRCH2-, and -NR-C(O)-; 
L je poveznik odabran iz skupine koja sadrži-NRCH>-, i -NR-C(O)-;
Hence, a further subject of the present invention is a process for preparing a compound according to formula (15), or salt thereof, 
£18-a) gdje R1 je vodikova ili dušikova zaštitna skupina. 56. Postupak za proizvodnju spoja u skladu sa sljedećom formulom (15) ili njegove soli: prsne
is represented by the following formula (V): wherein 
Y" je predstavljeno sljedećom formulom (V):
Alternatively, step (d) may be carried out under an overpressure within a range either of about 100 millibars to about 300 millibars, or of about 150 millibars to about 250 millibars. 
Alternativno, korak (d) se provodi pod tlakom unutar raspona od oko 100 milibara pa do 300 milibara ili od oko 150 milibara pa do 250 milibara.
Provided is at least one compound selected from compounds of Formula (I): 
PATENTNI ZAHTJEVI Spoj koje je odabran od spoja s Formulom (I):
The mooring buoy of claim 6, wherein the antenna is further configured to receive a signal from the booking system to indicate whether or not the vessel ID is associated with the mooring buoy. 
Plutača za privez (101) prema zahtjevu 6, naznačena time što je antena nadalje podešena da prima signal iz sustava za rezervaciju da bi se pokazalo da li je ID plovila povezan s plutačom za privez (101).
The waterproof liner according to claim 22, wherein the expandable watertight device comprises a material which expands in contact with water. 
Vodonepropusna obloga u skladu s patentnim zahtjevom 23, naznačena time, da ekspandirajući vodonepropusni uređaj (45) sadržava materijal koji se širi u dodiru s vodom.
The formulation according to (1) to (13) which has not been subjected to lyophillization during preparation of the formulation. 
Formulacija prema zahtjevu 10 ili 11 naznačena time da nije bila podvrgnuta liofilizaciji tijekom pripreme formulacije.
The results show that the r-hIL6-IL6R chimera, which was essentially undetectable in the crude harvest (FIG. 5), appeared as one of the major bands in the eluted fraction (94 fold purification by ELISA). 
Rezultati pokazuju da se himerni r-hIL6-IL6R, koji je u sirovom materijalu bio praktički nedetektabilan, javlja kao jedna od glavnih vrpci u eluiranoj frakciji (pročišćavanje od 94 puta, određeno ELISA testom).
R4 is a monophosphate, diphosphate or triphosphate ester; 
R* je monofosfatni, difosfatni ili trifosfatni ester; ili R* je skupina sa formulom
A method of controlling diseases on soybean plants caused by phytopathogens, which comprises applying to the soybean plants or to the locus thereof a composition according to claim 1. 
Postupak nadzora bolesti soje uzrokovanih fitopatogenima, naznačen time da se sastoji od primjene pripravka iz zahtjeva 1 na biljke soje, ili na njihov lokus.
The process of compounding of the elastomer used in this invention is standard in the art of elastomer manufacture, and numerous competent organisations are known which are capable of manufacturing such an elastomer and the appropriate colourant masterbatches. 
Postupak miješanja elastomera koji se koristi u ovom izumu je standardan u struci koja se bavi proizvodnjom elastomera i poznate su brojne kompetenine organizacije koje mogu proizvoditi takav elastomer i odgovarajuće glavne šarže sa sredstvom za bojenje.
There may be formulations according to the present invention in which the composition of the core is incompatible with the delayed release coating. 
Formulacija lijeka s odloženim otpuštanjem sukladno jednom od prethodnih patentnih zahtjeva, naznačeno time, da je pufer fosfatna sol.